Skip to main content
. Author manuscript; available in PMC: 2017 Oct 19.
Published in final edited form as: J Health Econ. 2016 Jun 24;49:97–108. doi: 10.1016/j.jhealeco.2016.06.001

Table 4.

Data for HIV, TB, and malaria example.

Intervention Target
population
Unit cost of
intervention (US$)
Total cost
(US$)
$ per DALY Adherence DALYS
averted
Ratio of benefits to costs
(cost-effectiveness)







1 2 3 4 5 6 7
HIV
Testing 1,700,000 17 28,900,000 38.27 0.39 294,512.67 0.0102
ART first line treatment 500,000 511 255,500,000 451.50 0.80 452,713.18 0.0018
TB
DOTS treatment 20,000 755 15,100,000 132.96 0.95 107,889.59 0.0071
Diagnosis 140,000 9.98 1,397,200 126.35 0.34 3759.78 0.0027
MDR-TB treatment 100 7595 759,500 521.96 0.80 1164.07 0.0015
Malaria
Treatment with ACTs 5,000,000 2.03 10,150,000 13.91 0.60 437,814.52 0.0431
Intermittent preventive treatment in pregnancy (IPTp) 945,000 0.30 283,500 25.68 0.40 4415.89 0.0156